Idiopathic Pulmonary Fibrosis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the incidence and prevalence of idiopathic pulmonary fibrosis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s IPF forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of IPF over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 11 IPF patient populations, as follows:
- Diagnosed incident cases of IPF.
- Diagnosed prevalent cases of IPF.
- Diagnosed prevalent cases of stage 1 IPF.
- Diagnosed prevalent cases of stage 2 IPF.
- Diagnosed prevalent cases of stage 3 IPF.
- Diagnosed prevalent cases of IPF with gastroesophageal reflux disease
- Diagnosed prevalent cases of IPF with emphysema.
- Diagnosed prevalent cases of IPF with pulmonary hypertension.
- Diagnosed prevalent cases of IPF with obstructive sleep apnea.
- Diagnosed drug-treated prevalent cases of IPF.
- Diagnosed non-drug-treated prevalent cases of IPF.
Note: Coverage may vary by country.
Table of contents
- Idiopathic Pulmonary Fibrosis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of idiopathic pulmonary fibrosis)
- Diagnosed prevalent cases of idiopathic pulmonary fibrosis
- Diagnosed incident cases of idiopathic pulmonary fibrosis
- Diagnosed prevalent cases of idiopathic pulmonary fibrosis by severity
- Diagnosed prevalent cases of idiopathic pulmonary fibrosis with gastroesophageal reflux disease
- Diagnosed prevalent cases of idiopathic pulmonary fibrosis with pulmonary hypertension
- Diagnosed prevalent cases of idiopathic pulmonary fibrosis with emphysema
- Diagnosed prevalent cases of idiopathic pulmonary fibrosis with obstructive sleep apnea
- Drug-treated prevalent cases of IPF
- Risk/protective factors applied to disease forecast models
- Reference materials
Mohani Latwal, B.P.T., M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, she worked as a deputy manager at an NGO. She received her bachelor’s degree in physiotherapy from Delhi University and her master’s degree in public health with a specialization in social epidemiology from the Tata Institute of Social Sciences in Mumbai.
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.